Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01895829 · ClinicalTrials.gov registry record · Early Phase 1
Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI
A Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT01895829: Clinical Trial Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01895829 is a Early Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01895829, a Early Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if ferumoxytol, when given at the time of a magnetic resonance imaging (MRI), can help researchers learn more about the spread of certain kinds of cancers. Ferumoxytol is designed to deliver iron to treat iron-deficiency anemia (low red blood cell counts) in patients with chronic kidney disease. In this study, it will be used as an MRI contrast. Contrasts are used by doctors in order to see MRI images more clearly.
Interventions
- DRUG Ferumoxytol
- PROCEDURE Magnetic Resonance Imaging (MRI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-09-12 |
| Est. Completion | 2021-09-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01895829
The ClinicalTrials.gov registry entry for NCT01895829 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferumoxytol is the first listed.
NCT01895829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01895829 about?
NCT01895829 is a clinical study titled "Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI". The goal of this clinical research study is to learn if ferumoxytol, when given at the time of a magnetic resonance imaging (MRI), can help researchers learn more about the spread of certain kinds of cancers. Ferumoxytol is designed to deliver iron to treat iron-deficiency anemia (low red blood cel...
What is the current status of trial NCT01895829?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2013-09-12. Estimated completion is 2021-09-07.
What interventions are being tested in trial NCT01895829?
The interventions under investigation include: Ferumoxytol (DRUG), Magnetic Resonance Imaging (MRI) (PROCEDURE).
Who is sponsoring clinical trial NCT01895829?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.